Longeveron’s infant heart-disease trial misses its primary endpoint
Longeveron ($LGVN) said its ELPIS II Phase 2b study in infants with hypoplastic left heart syndrome failed to meet its primary endpoint. The 40-patient trial assessed right-ventricular function after 12 months. The reported treatment difference was negative 0.7 percentage points, with a p-value of 0.8336, providing no statistically significant evidence of benefit on the primary measure. Exploratory outcomes also failed to establish statistically significant improvements, although the company rep
0